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S U M M A R Y
Background: The case of a central nervous system human herpes virus type 6 (HHV-6) and Toxoplasma
gondii co-infection after an umbilical cord blood transplantation in a chronic myelomonocytic leukaemia
patient is reported.
Case report: A 65-year-old Caucasian man underwent an umbilical cord blood transplantation within the
context of chronic myelomonocytic leukaemia. On day 37 post-graft, he presented with a severe
headache; PCRs of cerebrospinal ﬂuid and blood were positive for T. gondii and HHV-6. The patient was
treated with pyrimethamine and sulfadiazine associated with ganciclovir.
Conclusion: HHV-6 reactivation can trigger a reactivation of T. gondii. This case suggests that patients
who are seropositive for T. gondii and who present with HHV-6 reactivation should be monitored closely
for toxoplasmosis.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Reactivation of latent infections are life-threatening diseases in
immunocompromised patients. We describe a cerebral toxoplas-
mosis in a context of human herpes virus type 6 reactivation after
an umbilical cord blood transplantation.
2. Case report
A 65-year-old man was hospitalized in the haematology clinic
for an umbilical cord blood transplantation within the context of
chronic myelomonocytic leukaemia diagnosed in September
2013. The patient underwent 11 courses of azacitidine treatment
before transplantation. The patient’s medical history revealed him
to be seropositive for hepatitis A virus, Epstein–Barr virus, and
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Immunosuppressive therapy was started on September 15,
2014 with ciclosporin 300 mg daily and mycophenolate mofetil 1 g
twice a day. On September 18, 2014 he received two umbilical cord
blood transplants, with good tolerance, and remained in aplasia for
27 days. The patient was continued on antimicrobial prophylaxis
with ﬂuconazole and aciclovir during aplasia. On day 4 post-graft,
the anti-T. gondii IgG value was 91 IU/ml (positive value 8 IU/ml;
BioMe´rieux Vidas Toxo IgG) and anti-T. gondii IgM was negative
(BioMe´rieux Vidas Toxo IgM). On day 11 post-graft, a febrile
episode associated with an inﬂammatory reaction (C-reactive
protein 129 mg/l; normal value <3 mg/l) was treated successfully
with piperacillin. Antibiotic therapy was stopped on day 28 after
the recovery of blood marrow suppression. Corticosteroids
consisting of prednisone 1 mg/kg daily were started on day
20 after a skin rash appeared on the patient’s back and chest,
covering more than 50% of his body. Mycophenolate mofetil was
stopped on day 35 post-graft and ciclosporin was continued at
210 mg twice a day.
On day 37 post-graft, the patient presented a severe headache
and moderate fever. Blood count analysis revealed a leukocyteciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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computed tomography (CT) scan of the brain was performed, but
did not highlight any bleeding or infectious lesions. Cerebrospinal
ﬂuid (CSF) sampled on day 40 showed an increase in proteins
(2.69 g/l; normal range 0.15–0.45 g/l) and lactate (4.9 mmol/l;
normal range 0.6–2.2 mmol/l), and 98  106 red blood cells/l and
21  106 leukocytes/l, with a predominance of monocytes (68%)
and lymphocytes (20%). May–Gru¨nwald–Giemsa staining of the
CSF highlighted tachyzoites of T. gondii (Figure 1). The T. gondii load
measured using quantitative PCR was 1800 parasites/ml in CSF and
960 parasites/ml in blood. Viral investigation of the CSF yielded a
positive PCR for human herpes virus type 6 (BioMe´rieux CMV,
HHV-6, 7, 8, R-gene Assay) with a cycle threshold value of 37.6,
indicating a low viral load. HHV-6 genome quantiﬁcation in blood
was positive below 1000 copies/ml. The anti-Toxoplasma IgG value
was 43 IU/ml. Treatment for cerebral toxoplasmosis comprising
pyrimethamine (50 mg daily) and sulfadiazine (500 mg three
times daily) was started on day 41, for 6 weeks, associated with
antiviral treatment (ganciclovir, 10 mg/kg daily). The patient’s
clinical condition improved rapidly, with a regression of the
headache; he became apyretic on day 45. The anti-Toxoplasma IgG
value was 45 IU/ml.
CSF sampled on day 49 still displayed pleocytosis, with 32  106
lymphocytes/l. Toxoplasma real-time PCR was positive (39 para-
sites/ml), whereas HHV-6 PCR was negative. Magnetic resonance
imaging performed on the same day did not show any cerebral
abscess indicative of toxoplasmosis, but showed images suggestive
of graft-versus-host disease (GVHD). Real-time PCR performed on
the blood was positive for HHV-6 (1726 copies/ml) but negative for
T. gondii. Complete negativity of the HHV-6 quantitative PCR
occurred on day 74. The patient was discharged from hospital on
day 64, but was readmitted 10 days later for diarrhoea associated
with acute renal insufﬁciency inducing metabolic acidosis and
hyperkalaemia. A colonic biopsy showed grade 3 GVHD and
methylprednisolone was increased to 2 mg/kg daily. On day 78, the
patient became confused with meningeal syndrome and was
transferred to the intensive care unit. Blood cultures were positive
for Escherichia coli. CSF analysis showed poor cellularity (2  106
red blood cells/l and 4  106 leukocytes/l) associated with an
increase in lactate (7.2 mmol/l) and proteins (0.96 g/l). Real-time
PCR for T. gondii and HHV-6 performed on both CSF and blood were
negative. Empirical antibiotic therapy was started with piper-
acillin–tazobactam and gentamicin. The patient died on day 82 of
multiorgan failure.Figure 1. Tachyzoites of Toxoplasma gondii inside neutrophils in May-Gru¨nwald-
Giemsa-stained CSF samples (x1000).
Arrows show tachyzoites.3. Discussion
Umbilical cord blood transplantation (CBT) is an alternative
source of haematopoietic stem cells and is used in both paediatric
and adult cancer patients. The complete immaturity of the immune
system at birth has the advantages of inducing fewer immunolog-
ical complications and not requiring a perfect match between the
donor and recipient.
Patients undergoing allogeneic hematopoietic stem cell trans-
plantation (HSCT) are especially susceptible to severe toxoplas-
mosis, with an estimated incidence of between 0.4% and 8.7%
according to the endemicity.1 In HSCT patients, toxoplasmosis
mainly results from the reactivation of a latent infection rather
than primary infection. CBT is associated with an additional delay
in immune reconstitution, which is an important risk factor for
toxoplasmosis and other opportunistic diseases. The rate of severe
toxoplasmosis has been reported to be signiﬁcantly higher in CBT
patients than in those undergoing other types of allogeneic HSCT.1
In most cases, reactivation occurs during the second or third month
post-HSCT. To monitor the reactivation of toxoplasmosis, a weekly
PCR follow-up in blood is recommended, particularly during the
high-risk periods and for patients who are not receiving
prophylaxis.2 Indeed, the administration of primary chemopro-
phylaxis should be considered in high-risk HSCT recipients and
should be maintained for 6 months post-HSCT.2 Co-trimoxazole
prophylaxis is widely used in European HSCT centres.2 PCR is the
most powerful tool for the diagnosis of cerebral toxoplasmosis, as
direct staining is rarely positive and serology can give false results
in the immunosuppressed patient.
HHV-6 encephalitis appears to occur more frequently in
patients undergoing CBT.3 Some studies have suggested that the
increased prevalence of HHV-6 reactivation may be due to the
large number of immature T-cells present in umbilical cord blood.
HHV-6 represents an important emerging pathogen responsible
for central nervous system (CNS) complications accompanying
HSCT.3 The diagnosis of HHV-6 meningoencephalitis includes
neurological manifestations and positive detection of HHV-6 DNA
in the CSF, in the absence of any other identiﬁable pathogen.4
Mortality rates attributable to HHV-6 meningitis remain high, and
many survivors present cognitive sequelae.3 HHV-6 reactivation
has also been associated with an increased risk of GVHD, cytopenia,
opportunistic infections, and fever.3 Initially developed to target
human cytomegalovirus infection, ganciclovir has been shown to
be effective against HHV-6 in both in vitro and in vivo studies.
Thus, the American Society of Transplantation recommends the
use of ganciclovir and foscarnet as ﬁrst-line therapy for HHV-6
encephalitis.5,6
The concomitant detection of DNA for both T. gondii and HHV-6
in the CSF has only been reported once, in a retrospective analysis
of 181 CSF samples from patients with suspected viral meningitis.7
This co-infection was observed in an HIV-infected patient, but no
detailed description of the neurological signs was mentioned in
that report. A case of unilateral panuveitis associated with HHV-6
and T. gondii co-infection has also been described.8 Clinical
symptoms were suggestive of ocular toxoplasmosis and the
evolution was favourable after anti-Toxoplasma and antiviral
combination treatment. The pathogenicity of HHV-6 is not well
understood, but it could participate in the reactivation of T. gondii.
The primary risk factor for toxoplasmosis in the patient
presented here was CBT without anti-Toxoplasma prophylaxis.
However, although transient, the concomitant reactivation of
HHV-6 could have played a role in the occurrence of the
toxoplasmosis. Both HHV-6 and T. gondii show neurotropism
and a latency stage in the CNS, and HHV-6 is also known to
replicate in CD4+ cells and deplete T-cells, which may favour
intracellular opportunistic pathogens such as Toxoplasma.9 This
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gondii and infected with murine cytomegalovirus (MCMV).10 Acute
MCMV infection in mice was associated with a striking decrease in
lung CD4+ cells and an increased rate of pulmonary toxoplasmosis.
In conclusion, the ﬁrst case of a CNS T. gondii and HHV-6 co-
infection in a CBT recipient is reported herein. This case suggests
that patients who are seropositive for Toxoplasma and who present
with HHV-6 reactivation should to be monitored closely for
toxoplasmosis. Data on HHV-6 and Toxoplasma co-infection are
scarce and further clinical studies are required to clarify the link
between HHV-6 and Toxoplasma reactivations.
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